Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 689

1.

DNA methylation disruption reshapes the hematopoietic differentiation landscape.

Izzo F, Lee SC, Poran A, Chaligne R, Gaiti F, Gross B, Murali RR, Deochand SD, Ang C, Jones PW, Nam AS, Kim KT, Kothen-Hill S, Schulman RC, Ki M, Lhoumaud P, Skok JA, Viny AD, Levine RL, Kenigsberg E, Abdel-Wahab O, Landau DA.

Nat Genet. 2020 Mar 23. doi: 10.1038/s41588-020-0595-4. [Epub ahead of print]

PMID:
32203468
2.

ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms.

Viaud M, Abdel-Wahab O, Gall J, Ivanov S, Guinamard R, Sore S, Merlin J, Ayrault M, Guilbaud E, Jacquel A, Auberger P, Wang N, Levine RL, Tall AR, Yvan-Charvet L.

Cell Rep. 2020 Mar 10;30(10):3397-3410.e5. doi: 10.1016/j.celrep.2020.02.056.

3.

Detection of Marker-Free Precision Genome Editing and Genetic Variation through the Capture of Genomic Signatures.

Billon P, Nambiar TS, Hayward SB, Zafra MP, Schatoff EM, Oshima K, Dunbar A, Breinig M, Park YC, Ryu HS, Tschaharganeh DF, Levine RL, Baer R, Ferrando A, Dow LE, Ciccia A.

Cell Rep. 2020 Mar 10;30(10):3280-3295.e6. doi: 10.1016/j.celrep.2020.02.068.

4.

The Clinical Management of Clonal Hematopoiesis: Creation of a Clonal Hematopoiesis Clinic.

Bolton KL, Zehir A, Ptashkin RN, Patel M, Gupta D, Sidlow R, Papaemmanuil E, Berger MF, Levine RL.

Hematol Oncol Clin North Am. 2020 Apr;34(2):357-367. doi: 10.1016/j.hoc.2019.11.006. Epub 2020 Jan 18. Review.

PMID:
32089215
5.

Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe-/- Mice.

Tang Y, Liu W, Wang W, Fidler T, Woods B, Levine RL, Tall AR, Wang N.

Cardiovasc Drugs Ther. 2020 Feb 21. doi: 10.1007/s10557-020-06943-9. [Epub ahead of print]

PMID:
32086626
6.

Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia.

Uckelmann HJ, Kim SM, Wong EM, Hatton C, Giovinazzo H, Gadrey JY, Krivtsov AV, Rücker FG, Döhner K, McGeehan GM, Levine RL, Bullinger L, Vassiliou GS, Armstrong SA.

Science. 2020 Jan 31;367(6477):586-590. doi: 10.1126/science.aax5863.

PMID:
32001657
7.

Driver mutations in acute myeloid leukemia.

Kishtagari A, Levine RL, Viny AD.

Curr Opin Hematol. 2020 Mar;27(2):49-57. doi: 10.1097/MOH.0000000000000567.

PMID:
31972687
8.

Low-Dose Naltrexone reduces symptoms in Stiff-Person Syndrome.

Zappaterra M, Shouse E, Levine RL.

Med Hypotheses. 2020 Jan 2;137:109546. doi: 10.1016/j.mehy.2019.109546. [Epub ahead of print]

PMID:
31954293
9.

ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.

Xu G, Chhangawala S, Cocco E, Razavi P, Cai Y, Otto JE, Ferrando L, Selenica P, Ladewig E, Chan C, Da Cruz Paula A, Witkin M, Cheng Y, Park J, Serna-Tamayo C, Zhao H, Wu F, Sallaku M, Qu X, Zhao A, Collings CK, D'Avino AR, Jhaveri K, Koche R, Levine RL, Reis-Filho JS, Kadoch C, Scaltriti M, Leslie CS, Baselga J, Toska E.

Nat Genet. 2020 Feb;52(2):198-207. doi: 10.1038/s41588-019-0554-0. Epub 2020 Jan 13.

PMID:
31932695
10.

Nonautoimmune Hyperthyroidism Caused by a Somatic Mosaic GNAS Mutation Involving Part of the Thyroid Gland.

França MM, Levine RL, Pappa T, Ilaka-Chibuluzo S, Rothberger GD, Dumitrescu AM, Refetoff S.

Thyroid. 2020 Feb 7. doi: 10.1089/thy.2019.0471. [Epub ahead of print]

PMID:
31910104
11.

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.

Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, Stock W, Larson RA, Levine RL, Tallman MS, Park JH, Kerr C, Przychodzen B, Sekeres MA, Kalaycio ME, Carraway HE, Hamilton BK, Sobecks R, Gerds A, Mukherjee S, Nazha A, Maciejewski JP, Advani AS.

Blood Adv. 2019 Dec 23;3(24):4228-4237. doi: 10.1182/bloodadvances.2019000925.

12.

Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor.

Nieborowska-Skorska M, Paietta EM, Levine RL, Fernandez HF, Tallman MS, Litzow MR, Skorski T.

Blood Adv. 2019 Dec 10;3(23):4050-4054. doi: 10.1182/bloodadvances.2019000756. No abstract available.

13.

T cell-derived interferon-γ programs stem cell death in immune-mediated intestinal damage.

Takashima S, Martin ML, Jansen SA, Fu Y, Bos J, Chandra D, O'Connor MH, Mertelsmann AM, Vinci P, Kuttiyara J, Devlin SM, Middendorp S, Calafiore M, Egorova A, Kleppe M, Lo Y, Shroyer NF, Cheng EH, Levine RL, Liu C, Kolesnick R, Lindemans CA, Hanash AM.

Sci Immunol. 2019 Dec 6;4(42). pii: eaay8556. doi: 10.1126/sciimmunol.aay8556.

PMID:
31811055
14.

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.

Yue L, Sharma V, Horvat NP, Akuffo AA, Beatty MS, Murdun C, Colin C, Billington JMR, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville LN, Pinilla-Ibarz J, Reuther GW, Wright KL, Conti C, Lee JY, Zheng X, Ng PY, Martin MW, Marshall CG, Koomen JM, Levine RL, Verma A, Grimes HL, Sotomayor EM, Shao Z, Epling-Burnette PK.

Blood. 2020 Jan 16;135(3):191-207. doi: 10.1182/blood.2019895326.

PMID:
31750881
15.

Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.

Santos FPS, Getta B, Masarova L, Famulare C, Schulman J, Datoguia TS, Puga RD, Alves Paiva RM, Arcila ME, Hamerschlak N, Kantarjian HM, Levine RL, Campregher PV, Rampal RK, Verstovsek S.

Leukemia. 2020 Mar;34(3):799-810. doi: 10.1038/s41375-019-0603-9. Epub 2019 Oct 18.

PMID:
31628430
16.

Loss of methionine sulfoxide reductases increases resistance to oxidative stress.

Lai L, Sun J, Tarafdar S, Liu C, Murphy E, Kim G, Levine RL.

Free Radic Biol Med. 2019 Dec;145:374-384. doi: 10.1016/j.freeradbiomed.2019.10.006. Epub 2019 Oct 10.

PMID:
31606431
17.

Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.

Yoshimi A, Lin KT, Wiseman DH, Rahman MA, Pastore A, Wang B, Lee SC, Micol JB, Zhang XJ, de Botton S, Penard-Lacronique V, Stein EM, Cho H, Miles RE, Inoue D, Albrecht TR, Somervaille TCP, Batta K, Amaral F, Simeoni F, Wilks DP, Cargo C, Intlekofer AM, Levine RL, Dvinge H, Bradley RK, Wagner EJ, Krainer AR, Abdel-Wahab O.

Nature. 2019 Oct;574(7777):273-277. doi: 10.1038/s41586-019-1618-0. Epub 2019 Oct 2.

PMID:
31578525
18.

Evaluating Clonal Hematopoiesis in Tumor-Infiltrating Leukocytes in Breast Cancer and Secondary Hematologic Malignancies.

Comen EA, Bowman RL, Selenica P, Kleppe M, Farnoud NR, Pareja F, Weigelt B, Hill CE, Alon A, Geyer FC, Akturk G, Reis-Filho JS, Norton L, Levine RL.

J Natl Cancer Inst. 2020 Jan 1;112(1):107-110. doi: 10.1093/jnci/djz157.

PMID:
31504684
19.

Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation.

Viny AD, Bowman RL, Liu Y, Lavallée VP, Eisman SE, Xiao W, Durham BH, Navitski A, Park J, Braunstein S, Alija B, Karzai A, Csete IS, Witkin M, Azizi E, Baslan T, Ott CJ, Pe'er D, Dekker J, Koche R, Levine RL.

Cell Stem Cell. 2019 Nov 7;25(5):682-696.e8. doi: 10.1016/j.stem.2019.08.003. Epub 2019 Sep 5.

PMID:
31495782
20.

Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia.

Barth BM, Wang W, Toran PT, Fox TE, Annageldiyev C, Ondrasik RM, Keasey NR, Brown TJ, Devine VG, Sullivan EC, Cote AL, Papakotsi V, Tan SF, Shanmugavelandy SS, Deering TG, Needle DB, Stern ST, Zhu J, Liao J, Viny AD, Feith DJ, Levine RL, Wang HG, Loughran TP Jr, Sharma A, Kester M, Claxton DF.

Blood Adv. 2019 Sep 10;3(17):2598-2603. doi: 10.1182/bloodadvances.2018021295. No abstract available.

21.

Overcoming adaptive therapy resistance in AML by targeting immune response pathways.

Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, Abendroth J, O'Brien E, Hoyt SB, Berman E, Famulare CA, Mulloy JC, Levine RL, Perentesis JP, Thomas CJ, Starczynowski DT.

Sci Transl Med. 2019 Sep 4;11(508). pii: eaaw8828. doi: 10.1126/scitranslmed.aaw8828.

22.

Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms.

Shank K, Dunbar A, Koppikar P, Kleppe M, Teruya-Feldstein J, Csete I, Bhagwat N, Keller M, Kilpivaara O, Michor F, Levine RL, de Vargas Roditi L.

Haematologica. 2020 Mar;105(3):e91-e94. doi: 10.3324/haematol.2018.203729. Epub 2019 Aug 14. No abstract available.

23.

Repurposing the Pummerer Rearrangement: Determination of Methionine Sulfoxides in Peptides.

Woodroofe CC, Ivanic J, Monti S, Levine RL, Swenson RE.

Chembiochem. 2020 Feb 17;21(4):508-516. doi: 10.1002/cbic.201900463. Epub 2019 Oct 25.

24.

Beyond rescue, treatment, and prevention: understanding the broader impact of the opioid epidemic at the state level.

Fassbender L, Zander GB, Levine RL.

Am J Manag Care. 2019 Jul;25(13 Suppl):S239-S240. No abstract available.

25.

Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week.

Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, Zeiher A, Jaiswal S, Schulz C, Blankstein R, Bolton KL, Steensma D, Levine RL, Ebert BL.

J Am Coll Cardiol. 2019 Jul 30;74(4):567-577. doi: 10.1016/j.jacc.2019.06.007. Review.

PMID:
31345432
26.

Challenges and approaches to implementing master/basket trials in oncology.

Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR.

Blood Adv. 2019 Jul 23;3(14):2237-2243. doi: 10.1182/bloodadvances.2019031229.

27.

Risk of disease progression in low-risk MDS is linked to distinct epigenetic subtypes.

Qin T, Sotzen J, Rampal RK, Rapaport FT, Levine RL, Klimek V, Nimer SD, Figueroa ME.

Leukemia. 2019 Nov;33(11):2753-2757. doi: 10.1038/s41375-019-0518-5. Epub 2019 Jul 22. No abstract available.

28.

Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation In Vivo.

Woods B, Chen W, Chiu S, Marinaccio C, Fu C, Gu L, Bulic M, Yang Q, Zouak A, Jia S, Suraneni PK, Xu K, Levine RL, Crispino JD, Wen QJ.

Clin Cancer Res. 2019 Oct 1;25(19):5901-5912. doi: 10.1158/1078-0432.CCR-18-4089. Epub 2019 Jun 19.

PMID:
31217200
29.

Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.

Duy C, Teater M, Garrett-Bakelman FE, Lee TC, Meydan C, Glass JL, Li M, Hellmuth JC, Mohammad HP, Smitheman KN, Shih AH, Abdel-Wahab O, Tallman MS, Guzman ML, Muench D, Grimes HL, Roboz GJ, Kruger RG, Creasy CL, Paietta EM, Levine RL, Carroll M, Melnick AM.

Cancer Discov. 2019 Jul;9(7):872-889. doi: 10.1158/2159-8290.CD-19-0106. Epub 2019 May 10.

PMID:
31076479
30.

Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis.

Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo WL, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw KL, Bhattacharyya S, Bishop MR, Artz A, Thirman MJ, Moliterno A, Ji P, Levine RL, Godley LA, Steidl U, Bieker JJ, List AF, Saunthararajah Y, He C, Verma A, Wickrema A.

Cancer Discov. 2019 Jun;9(6):778-795. doi: 10.1158/2159-8290.CD-18-1138. Epub 2019 Apr 3.

PMID:
30944118
31.

Genetic and epigenetic determinants of AML pathogenesis.

Cai SF, Levine RL.

Semin Hematol. 2019 Apr;56(2):84-89. doi: 10.1053/j.seminhematol.2018.08.001. Epub 2018 Aug 22. Review.

PMID:
30926095
32.

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia.

Levine RL, Valk PJM.

Haematologica. 2019 May;104(5):868-871. doi: 10.3324/haematol.2018.205955. Epub 2019 Mar 28. No abstract available.

33.

Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.

Chen D, Xia S, Wang M, Lin R, Li Y, Mao H, Aguiar M, Famulare CA, Shih AH, Brennan CW, Gao X, Pan Y, Liu S, Fan J, Jin L, Song L, Zhou A, Mukherjee J, Pieper RO, Mishra A, Peng J, Arellano M, Blum WG, Lonial S, Boggon TJ, Levine RL, Chen J.

Cancer Discov. 2019 Jun;9(6):756-777. doi: 10.1158/2159-8290.CD-18-1040. Epub 2019 Mar 12.

PMID:
30862724
34.

Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.

Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, Dirnhofer S, Dettmer MS, Simillion C, Kaufmann BA, Chiu S, Keller M, Kleppe M, Hilpert M, Buser AS, Passweg JR, Radimerski T, Skoda RC, Levine RL, Meyer SC.

J Clin Invest. 2019 Mar 4;130:1596-1611. doi: 10.1172/JCI98785. eCollection 2019 Mar 4.

35.

Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.

Loberg MA, Bell RK, Goodwin LO, Eudy E, Miles LA, SanMiguel JM, Young K, Bergstrom DE, Levine RL, Schneider RK, Trowbridge JJ.

Leukemia. 2019 Jul;33(7):1635-1649. doi: 10.1038/s41375-018-0368-6. Epub 2019 Jan 28.

36.

Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.

Merlinsky TR, Levine RL, Pronier E.

Clin Cancer Res. 2019 May 15;25(10):2956-2962. doi: 10.1158/1078-0432.CCR-18-3777. Epub 2019 Jan 17. Review.

PMID:
30655313
37.

Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.

Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Maloy M, Castro-Malaspina H, Giralt SA, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1142-1151. doi: 10.1016/j.bbmt.2019.01.002. Epub 2019 Jan 6.

PMID:
30625392
38.

Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 V617F Mice.

Wang W, Liu W, Fidler T, Wang Y, Tang Y, Woods B, Welch C, Cai B, Silvestre-Roig C, Ai D, Yang YG, Hidalgo A, Soehnlein O, Tabas I, Levine RL, Tall AR, Wang N.

Circ Res. 2018 Nov 9;123(11):e35-e47. doi: 10.1161/CIRCRESAHA.118.313283.

39.

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.

Rampal RK, Mascarenhas JO, Kosiorek HE, Price L, Berenzon D, Hexner E, Abboud CN, Kremyanskaya M, Weinberg RS, Salama ME, Menghrajani K, Najfeld V, Sandy L, Heaney ML, Levine RL, Mesa RA, Dueck AC, Goldberg JD, Hoffman R.

Blood Adv. 2018 Dec 26;2(24):3572-3580. doi: 10.1182/bloodadvances.2018019661.

40.

Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.

Xiao W, Goldberg AD, Famulare CA, Devlin SM, Nguyen NT, Sim S, Kabel CC, Patel MA, McGovern EM, Patel A, Schulman J, Dunbar AJ, Epstein-Peterson ZD, Menghrajani KN, Getta BM, Cai SF, Geyer MB, Glass JL, Taylor J, Viny AD, Levine RL, Zhang Y, Giralt SA, Klimek V, Tallman MS, Roshal M.

Haematologica. 2019 Jul;104(7):1378-1387. doi: 10.3324/haematol.2018.203018. Epub 2018 Dec 6.

41.

PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.

Xiao W, Bharadwaj M, Levine M, Farnhoud N, Pastore F, Getta BM, Hultquist A, Famulare C, Medina JS, Patel MA, Gao Q, Lewis N, Pichardo J, Baik J, Shaffer B, Giralt S, Rampal R, Devlin S, Cimera R, Zhang Y, E Arcila M, Papaemmanuil E, Levine RL, Roshal M.

Blood Adv. 2018 Dec 11;2(23):3526-3539. doi: 10.1182/bloodadvances.2018023531. Erratum in: Blood Adv. 2019 Apr 9;3(7):956.

42.

Drosophila methionine sulfoxide reductase A (MSRA) lacks methionine oxidase activity.

Tarafdar S, Kim G, Levine RL.

Free Radic Biol Med. 2019 Feb 1;131:154-161. doi: 10.1016/j.freeradbiomed.2018.12.001. Epub 2018 Dec 4.

PMID:
30529269
43.

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.

Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S.

Blood. 2019 Feb 14;133(7):676-687. doi: 10.1182/blood-2018-08-869008. Epub 2018 Dec 3.

44.

Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900.

Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta E, Racevskis J, Levine RL, Patel JP, Abdel-Wahab O, Ketterling RP, Dewald GW, Bennett JM, Rowe JM, Lazarus HM, Tallman MS.

Haematologica. 2019 Apr;104(4):e147-e150. doi: 10.3324/haematol.2018.197277. Epub 2018 Nov 22. No abstract available.

45.

Targeting the CALR interactome in myeloproliferative neoplasms.

Pronier E, Cifani P, Merlinsky TR, Berman KB, Somasundara AVH, Rampal RK, LaCava J, Wei KE, Pastore F, Maag JL, Park J, Koche R, Kentsis A, Levine RL.

JCI Insight. 2018 Nov 15;3(22). pii: 122703. doi: 10.1172/jci.insight.122703.

46.

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.

Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein EM, Intlekofer AM.

Cancer Discov. 2018 Dec;8(12):1540-1547. doi: 10.1158/2159-8290.CD-18-0877. Epub 2018 Oct 24.

47.

Oxidation of Methionine 77 in Calmodulin Alters Mouse Growth and Behavior.

Marimoutou M, Springer DA, Liu C, Kim G, Levine RL.

Antioxidants (Basel). 2018 Oct 13;7(10). pii: E140. doi: 10.3390/antiox7100140.

48.

TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.

Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontán L, Rivas MA, Pawlikowska P, Armand M, Mouly E, Torres-Martin M, Doane AS, Calvo Fernandez MT, Durant M, Della-Valle V, Teater M, Cimmino L, Droin N, Tadros S, Motanagh S, Shih AH, Rubin MA, Tam W, Aifantis I, Levine RL, Elemento O, Inghirami G, Green MR, Figueroa ME, Bernard OA, Aoufouchi S, Li S, Shaknovich R, Melnick AM.

Cancer Discov. 2018 Dec;8(12):1632-1653. doi: 10.1158/2159-8290.CD-18-0657. Epub 2018 Oct 1.

49.

HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.

Sun Y, Zhou B, Mao F, Xu J, Miao H, Zou Z, Phuc Khoa LT, Jang Y, Cai S, Witkin M, Koche R, Ge K, Dressler GR, Levine RL, Armstrong SA, Dou Y, Hess JL.

Cancer Cell. 2018 Oct 8;34(4):643-658.e5. doi: 10.1016/j.ccell.2018.08.018. Epub 2018 Sep 27.

50.

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL.

J Clin Invest. 2018 Oct 1;128(10):4743. doi: 10.1172/JCI124920. Epub 2018 Sep 17. No abstract available.

Supplemental Content

Loading ...
Support Center